Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05814406
Status:
RECRUITING
Last Update Posted:
2023-05-06
First Post:
2023-04-03
Brief Title:
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
Sponsor:
JW Pharmaceutical
Organization:
JW Pharmaceutical
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Parallel Phase Ⅲ Study to Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With C2202 and C2204
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter randomized double blind placebo controlled parallel phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204
Detailed Description:
A multicenter randomized double blind placebo controlled parallel phase Ⅲ study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None